Top

Supportive Care in Cancer

Published in:

01-02-2011 | Original Article

Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE

Authors: John B. Bossaer, Philip D. Hall, Elizabeth Garrett-Mayer

Published in: Supportive Care in Cancer | Issue 2/2011

Abstract

Purpose

This study seeks to determine the incidence of vancomycin-resistant enterococci (VRE) infection in high-risk neutropenic fever patients colonized with VRE and to determine patient characteristics associated with VRE infection.

Methods

We conducted a retrospective, single-center, unmatched case-control study. Fifty-three VRE-colonized, high-risk patients with neutropenic fever were identified between January 2006 and February 2009. The two most common diagnoses/conditions included acute myeloid leukemia and hematopoietic stem cell transplantation. Data collected included days of neutropenia, days of fever, demographic data, culture results, and antimicrobial therapy.

Results

Twenty of the 53 patients (38%) with VRE colonization developed a VRE infection. The most common VRE infections were bacteremias (26%). The presence of neutropenia lasting longer than 7 days was associated with the development of VRE infection in this high-risk population colonized with VRE. The timeframe to develop VRE infection varied from 1 day to 2 weeks.

Conclusion

For patients colonized with VRE, approximately 38% of high-risk neutropenic patients developed a VRE infection. This is the first study to specifically evaluate the incidence of VRE infections in febrile neutropenic patients colonized with VRE. Future research into the use and efficacy of empiric VRE coverage is needed.

Hughes WT, Armstrong D, Bodey GP et al (2002) Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751PubMedCrossRef

National Comprehensive Cancer Network. 2008 Prevention and treatment of cancer-related infections. [http://www.nccn.org/professionals/physician_gls/PDF/infections.pdf] Accessed 12/11/08

Bhavnani SM, Drake JA, Forrest A et al (2000) A nationwide, multicenter, case-control study comparing risk factors, treatment and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 36:145–158PubMedCrossRef

Vergis EN, Hayden MK, Chow JW et al (2001) Determination of vancomycin resistance and mortality rates in enterococcal bacteremia: a prospective multicenter study. Ann Intern Med 135:484–492PubMed

DiazGranados CA, Jernigan JA (2005) Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. Jour Infect Dis 191:588–595CrossRef

Olivier CN, Blake RK, Steed LL et al (2008) Risk of vancomycin-resistant enterococcus (VRE) bloodstream infection among patients colonized with VRE. Infect Control Hosp Epidemiol 29:404–409PubMedCrossRef

Zaas AK, Song X, Tucker P et al (2002) Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis 35:1139–1146PubMedCrossRef

Matar MJ, Tarrand J, Raad I et al (2006) Colonization and infection with vancomycin-resistant enterococcus among patients with cancer. Am Jour Infect Control 34:534–536CrossRef

Weinstock DM, Conlon M, Iovino C et al (2007) Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 13:615–621PubMedCrossRef

10.

Pertel PE, Bernado P, Fogarty C et al (2008) Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 46:1142–1151PubMedCrossRef

11.

Gerson SL, Kaplan SL, Bruss JB et al (2002) Hematolog effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 46:2723–2726PubMedCrossRef

12.

Poutsiaka DD, Skiffington S, Miller KB et al (2007) Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. Jour Infect 54:567–571CrossRef

13.

Smith PF, Birmingham MC, Noskin GA et al (2003) Safety, efficacy, and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann Oncol 14:795–801PubMedCrossRef

14.

Jaksic B, Martinelli G, Perez-Oteyza J et al (2006) Efficacy and safety of linezolid compared to vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 42:597–607PubMedCrossRef

15.

Poutsiaka DD, Skiffington S, Miller KB et al (2007) Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. Jour of Infect 54:567–571CrossRef

16.

Eys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Associatation of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12:555–560

17.

Dubberke ER, Hollands JM, Georgantopoulos P et al (2006) Vancomycin-resistant enterococcal bloodstream infections on a hematopoietic stem cell transplant unit: are the sick getting sicker? Bone Marrow Transplant 38:813–819PubMedCrossRef

18.

Rostein C, Mandell LA, Goldberg N (1997) Fluoroquinolone prophylaxis for profoundly neutropenic cancer patients: a meta-analysis. Curr Opin Oncol 4(Suppl 2):S2–S7

19.

Cruciani M, Rampazzo R, Malena M et al (1996) Prophylaxis with fluoroquinolones in neutropenic patients: a meta-analysis. Clin Infect Dis 23:795–805PubMedCrossRef

20.

Carratala J, Fernandez-Sevilla A, Tubau F et al (1995) Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who received prophylactic norfloxacin. Clin Infect Dis 20:557–560PubMedCrossRef

21.

Kern WV, Andriof E, Oethinger M et al (1994) Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 38:681–687PubMed

Title: Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE
Authors: John B. Bossaer
Philip D. Hall
Elizabeth Garrett-Mayer
Publication date: 01-02-2011
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 2/2011
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-009-0808-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2011

The Fatigue Symptom Inventory: a systematic review of its psychometric properties

The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control: a Korean multicenter study

Psychological distress and needs of cancer patients: a prospective comparison between the diagnostic and the therapeutic phase

Factors that influence the efficacy of bereavement life review therapy for spiritual well-being: a qualitative analysis

Progress of oral care and reduction of oral mucositis—a pilot study in a hematopoietic stem cell transplantation ward

Screening for psychological distress in patients with lung cancer: results of a clinical audit evaluating the use of the patient Distress Thermometer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer